Proinflammatory cytokine pathways and related mediators

Proinflammatory cytokine pathways and related mediators represent a complex network of signaling proteins and intracellular cascades that initiate and amplify the immune system's inflammatory response. Key molecular players include cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which act as intercellular messengers by binding to high-affinity cell surface receptors (StatPearls, 2023). This binding triggers downstream signaling events, most notably the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and Nuclear Factor-kappa B (NF-kappaB) pathways, leading to the transcription of genes involved in cell recruitment and activation (Nature Reviews Immunology, 2018). While essential for host defense, dysregulation of these pathways is a primary driver of chronic inflammatory and autoimmune disorders, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (NIH, 2022). Therapeutic strategies targeting these pathways include the use of monoclonal antibodies to neutralize specific cytokines or their receptors, as well as small-molecule inhibitors that block intracellular signaling enzymes, effectively dampening the inflammatory cascade (PubMed, 2021). These interventions have revolutionized the treatment of chronic inflammation but require careful monitoring due to the increased risk of serious infections and other immune-related adverse effects.

Other names

Inflammatory cytokine signalingPro-inflammatory cascadeCytokine-mediated signaling pathways

Inhibition of proinflammatory signaling through cytokine neutralization, receptor antagonism, or intracellular kinase inhibition.